

Summary
This continuing education overview highlights a cross-disciplinary learning path across data analysis, AI, healthcare, medical research, and clinical context. The goal is not to claim clinical authority, but to build the domain fluency needed to interpret healthcare data with greater clarity, care, and practical judgment.
Key Points

Summary
AI strategy increasingly depends on more than models, applications, prompts, and productivity tools. Canada’s recent work with TELUS on sovereign AI infrastructure offers a useful example of how compute capacity, data residency, jurisdiction, energy use, cooling systems, and governance are becoming part of the AI readiness conversation. For data analytics professionals, the announcement highlights a broader shift: responsible AI adoption requires strong data foundations, reliable infrastructure, clear governance, and careful attention to sustainability and public accountability.
Key Points
Read more: Sovereign AI Infrastructure and the New Shape of AI Strategy

Abstract
Lundbeck’s AI Days offers a practical example of how organizations can approach AI adoption as a structured capability-building effort rather than a simple technology rollout. By connecting AI to business strategy, involving senior leadership, offering hands-on training, and emphasizing responsible use, Lundbeck shows how companies can help employees build confidence while aligning AI experimentation with clear organizational goals. For data and analytics teams, the example reinforces an important point: AI works best when it builds on strong data foundations, clear workflows, sound governance, and measurable business value.
Key Points
Read more: Lundbeck’s AI Days Show How Companies Can Make AI Adoption Practical

Lilly’s TuneLab platform and new AI supercomputing infrastructure enable biotech partners to accelerate drug discovery using secure, high-value machine learning models trained on decades of research data.
Abstract
Eli Lilly has introduced TuneLab, an AI platform that provides biotech companies access to drug discovery models trained on more than $1 billion of proprietary research data. The platform uses federated learning to let partners apply and improve these models without exchanging raw datasets. At the same time, Lilly is building one of the most powerful AI supercomputers in the pharmaceutical industry to support large-scale model development. Together, these moves represent a shift toward AI-augmented scientific workflows, where data, compute, and collaboration accelerate early-stage drug discovery.
Key Points
Page 1 of 8